One of the S&P 500’s big winners for Monday February 15 was Vertex Pharmaceuticals Incorporated (VRTX) as the company’s stock climbed 4.42% to $83.23 on volume of 2.77 million shares.
The stock opened at $81.94 and saw an intraday low of $79.50 and an intraday high of $83.81. All told, the day saw a per-share gain of $3.52. The stock’s average daily volume of 2.24 million and 245.72 million shares outstanding. Vertex Pharmaceuticals Incorporated now has a 50-day SMA is $107.35 and 200-day SMA is $120.81, and it has a 52-week high of $143.45 and a 52-week low of $78.51.
Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets.
Based out of Boston, MA, Vertex Pharmaceuticals Incorporated has 1,830 employees and, after today’s trading, reached a market cap of $20.45 billion. Its P/S ratio is 18.97, P/B ratio is 22.2, and P/FCF ratio is -42.4.
For a complete fundamental analysis analysis of Vertex Pharmaceuticals Incorporated, check out Equities.com’s Stock Valuation Analysis report for VRTX. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.
The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.
While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.
For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer